Shares of Nuvation Bio, Inc. (NUVB) tumbled 5.32% in pre-market trading on Thursday following the release of the company's second-quarter 2025 financial results. Despite meeting earnings per share (EPS) estimates and reporting significant revenue growth, investors appear concerned about the biotech firm's high expenses and substantial net loss.

Nuvation Bio reported a Q2 EPS of $(0.17), in line with analyst consensus estimates. The company's revenue surged to $4.833 million, marking a striking 236.79% increase from $1.435 million in the same period last year. However, this impressive top-line growth was overshadowed by concerning financial metrics that likely triggered the sell-off.

The biotech company's Q2 operating expenses ballooned to $65.846 million, resulting in an operating loss of $63.589 million. Furthermore, Nuvation Bio posted a net loss of $59.007 million for the quarter. These figures suggest that despite the revenue growth, the company's aggressive spending on research and development and other operational costs continues to weigh heavily on its bottom line. Investors may be growing impatient with the company's path to profitability, leading to the sharp decline in stock price despite the revenue beat.